Zajac Alexander E, Adams Austin S, Turner Justin H
Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University School of Medicine, Nashville, TN.
Int Forum Allergy Rhinol. 2015 Jun;5(6):524-32. doi: 10.1002/alr.21492. Epub 2015 Apr 20.
Probiotics have proven beneficial in a number of immune-mediated and allergic diseases. Several human studies have evaluated the efficacy of probiotics in allergic rhinitis; however, evidence for their use has yet to be firmly established. The current systematic review seeks to synthesize the results of available randomized trials.
In a systematic review and meta-analysis, the Medline, EMBASE, and Cochrane Library databases were reviewed and randomized controlled trials (RCTs) were extracted based on defined inclusion criteria. The effect of probiotics on Rhinitis Quality of Life (RQLQ) scores, Rhinitis Total Symptom Scores (RTSS), as well as total and antigen-specific serum immunoglobulin E (IgE) levels were evaluated by meta-analysis.
A total of 23 studies with 1919 patients were identified, including 21 double-blind RCTs and 2 randomized crossover studies. Multiple probiotic strains, study populations, and outcome measures were used in individual trials. Seventeen studies showed a significant clinical benefit from the use of probiotics in at least 1 outcome measure when compared to placebo, whereas 6 trials showed no benefit. Among the trials eligible for meta-analysis, the use of probiotics resulted in a significant improvement in RQLQ scores compared to placebo (standard mean difference [SMD] -2.23; p = 0.02). Probiotics had no effect on RTSS (SMD -0.36; p = 0.13) or total IgE levels (SMD 0.01; p = 0.94), although there was a trend toward a reduction in antigen-specific IgE (SMD 0.20; p = 0.06) in the placebo group compared to probiotic.
Probiotics may be beneficial in improving symptoms and quality of life in patients with allergic rhinitis; however, current evidence remains limited due to study heterogeneity and variable outcome measures. Additional high-quality studies are needed to establish appropriate recommendations.
益生菌已被证明对多种免疫介导性疾病和过敏性疾病有益。多项人体研究评估了益生菌在过敏性鼻炎中的疗效;然而,其使用依据尚未得到确凿证实。本系统评价旨在综合现有随机试验的结果。
在一项系统评价和荟萃分析中,检索了Medline、EMBASE和Cochrane图书馆数据库,并根据既定纳入标准提取随机对照试验(RCT)。通过荟萃分析评估益生菌对鼻炎生活质量(RQLQ)评分、鼻炎总症状评分(RTSS)以及总血清免疫球蛋白E(IgE)和抗原特异性血清IgE水平的影响。
共纳入23项研究,涉及1919例患者,包括21项双盲RCT和2项随机交叉研究。各试验使用了多种益生菌菌株、研究人群和结局指标。17项研究表明,与安慰剂相比,使用益生菌在至少一项结局指标上具有显著的临床益处,而6项试验未显示出益处。在符合荟萃分析条件的试验中,与安慰剂相比,使用益生菌可使RQLQ评分显著改善(标准化均数差[SMD] -2.23;p = 0.02)。益生菌对RTSS(SMD -0.36;p = 0.13)或总IgE水平(SMD 0.01;p = 0.94)无影响,尽管与益生菌组相比,安慰剂组的抗原特异性IgE有降低趋势(SMD 0.20;p = 0.06)。
益生菌可能有助于改善过敏性鼻炎患者的症状和生活质量;然而,由于研究的异质性和结局指标的多样性,目前的证据仍然有限。需要更多高质量的研究来制定合适的建议。